Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Gordon S Lynch. (2001) Novel therapies for muscular dystrophy and other muscle wasting conditions. Expert Opinion on Therapeutic Patents 11:4, pages 587-601.
Read now
Read now
Articles from other publishers (20)
Ziao Zong, Xiaodan Wei, Xingchen Yan & Yuhua Fan. (2018) Crystal structures and anticancer activities of five novel pyrazolone-enamine transition metal complexes with 4-benzoyl-3-methyl-1-phenyl-2-pyrazolin-5-one. Journal of Molecular Structure 1171, pages 333-339.
Crossref
Crossref
Nan Zhang, Yu-hua Fan, Zhen Zhang, Jian Zuo, Peng-fei Zhang, Qiang Wang, Shan-bin Liu & Cai-feng Bi. (2012) Syntheses, crystal structures and anticancer activities of three novel transition metal complexes with Schiff base derived from 2-acetylpyridine and l-tryptophan. Inorganic Chemistry Communications 22, pages 68-72.
Crossref
Crossref
Reem Smoum, Abraham Rubinstein, Valery M. Dembitsky & Morris Srebnik. (2012) Boron Containing Compounds as Protease Inhibitors. Chemical Reviews 112:7, pages 4156-4220.
Crossref
Crossref
Shuangyu Bi, Aidong Wang, Caifeng Bi, Yuhua Fan, Yan Xiao, Shanbin Liu & Qiang Wang. (2012) Coordination polymer of zinc based on chiral non-racemic trans-N,N′-bis-(2-hydroxy-1-naphthalidehydene)-(1R,2R)-cyclohexa-nediamine: Synthesis, crystal structure, novel coordinational models and anticancer activity. Inorganic Chemistry Communications 15, pages 167-171.
Crossref
Crossref
Yu-Hua Fan, Ai-Dong Wang, Cai-Feng Bi, Yan Xiao, Shuang-Yu Bi, Xia Zhang & Qiang Wang. (2011) Synthesis, crystal structure and anticancer activity of 2D-coordination polymer of cerium(III) with chiral Schiff base trans-N,N′-bis-(2-hydroxy-1-naphthalidehydene)-(1R,2R)-cyclohexanediamine. Synthetic Metals 161:15-16, pages 1552-1556.
Crossref
Crossref
GuoQing Shi, Qing Sun, HuanJie Yang, QingPing Dou, QianMin Deng, HaiOu Wang & GuangRong Zhong. (2010) Molecular modeling for the interaction between proteasome beta 5 subunit and organotin compounds. Science China Chemistry 53:11, pages 2387-2393.
Crossref
Crossref
A. Chiaviello, I. Paciello, I. Postiglione, E. Crescenzi & G. Palumbo. (2010) Combination of photodynamic therapy with aspirin in human‐derived lung adenocarcinoma cells affects proteasome activity and induces apoptosis. Cell Proliferation 43:5, pages 480-493.
Crossref
Crossref
Vesna Milacic & Q. Ping Dou. (2009) The tumor proteasome as a novel target for gold(III) complexes: Implications for breast cancer therapy. Coordination Chemistry Reviews 253:11-12, pages 1649-1660.
Crossref
Crossref
Vesna Milacic, Di Chen, Luca Ronconi, Kristin R. Landis-Piwowar, Dolores Fregona & Q. Ping Dou. (2006) A Novel Anticancer Gold(III) Dithiocarbamate Compound Inhibits the Activity of a Purified 20S Proteasome and 26S Proteasome in Human Breast Cancer Cell Cultures and Xenografts. Cancer Research 66:21, pages 10478-10486.
Crossref
Crossref
Carlos García-Echeverría. (2006) Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells. International Journal of Peptide Research and Therapeutics 12:1, pages 49-64.
Crossref
Crossref
Kenyon G Daniel, Di Chen, Shirley Orlu, Qiuzhi Cindy Cui, Fred R Miller & Q Ping Dou. (2005) Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Research 7:6.
Crossref
Crossref
David M. Smith, Kenyon G. Daniel, Zhigang Wang, Wayne C. Guida, Tak‐Hang Chan & Q. Ping Dou. (2003) Docking studies and model development of tea polyphenol proteasome inhibitors: Applications to rational drug design. Proteins: Structure, Function, and Bioinformatics 54:1, pages 58-70.
Crossref
Crossref
Aslamuzzaman Kazi, Kenyon G. Daniel, David M. Smith, Nagi B. Kumar & Q.Ping Dou. (2003) Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochemical Pharmacology 66:6, pages 965-976.
Crossref
Crossref
David M. Smith, Aslamuzzaman Kazi, Lisa Smith, Timothy E. Long, Bart Heldreth, Edward Turos & Q. Ping Dou. (2002) A Novel β-Lactam Antibiotic Activates Tumor Cell Apoptotic Program by Inducing DNA Damage. Molecular Pharmacology 61:6, pages 1348-1358.
Crossref
Crossref
BARRY HALLIWELL. (2002) Hypothesis: Proteasomal Dysfunction. Annals of the New York Academy of Sciences 962:1, pages 182-194.
Crossref
Crossref
Pascal Furet, Patricia Imbach, Peter Fuerst, Marc Lang, Maria Noorani, Johann Zimmermann & Carlos Garcı́a-Echeverrı́a. (2002) Structure-Based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-Like activity of the human 20S proteasome. Bioorganic & Medicinal Chemistry Letters 12:10, pages 1331-1334.
Crossref
Crossref
Markus Kaiser, Michael Groll, Christian Renner, Robert Huber & Luis Moroder. (2002) Das Grundgerüst von TMC-95A als mögliche Leitstruktur für reversible Proteasominhibitoren. Angewandte Chemie 114:5, pages 817-820.
Crossref
Crossref
Pascal Furet, Patricia Imbach, Peter Fürst, Marc Lang, Maria Noorani, Johann Zimmermann & Carlos Garcı́a-Echeverrı́a. (2001) Modeling of the Binding Mode of a Non-covalent Inhibitor of the 20S Proteasome. Application to Structure-Based Analogue Design. Bioorganic & Medicinal Chemistry Letters 11:10, pages 1321-1324.
Crossref
Crossref
C Garcı́a-Echeverrı́a, P Imbach, D France, P Fürst, M Lang, M Noorani, D Scholz, J Zimmermann & P Furet. (2001) A New Structural Class of Selective and Non-covalent Inhibitors of the Chymotrypsin-like Activity of the 20S Proteasome. Bioorganic & Medicinal Chemistry Letters 11:10, pages 1317-1319.
Crossref
Crossref
David C Swinney. (2001) Targeting protein ubiquitination for drug discovery. What is in the drug discovery toolbox?. Drug Discovery Today 6:5, pages 244-250.
Crossref
Crossref